Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05654506 · ClinicalTrials.gov registry record · Phase 2
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
A Phase 2 study of Proliferative Glomerulonephritis With Monoclonal IgG Deposits, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT05654506 is a Phase 2 study of Proliferative Glomerulonephritis With Monoclonal IgG Deposits that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 40 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT05654506, a Phase 2 study of Proliferative Glomerulonephritis With Monoclonal IgG Deposits, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
Conditions Studied
Interventions
- DRUG Daratumumab
Study Locations (4)
Florida
- Mayo Clinic - Jacksonville
Minnesota
- Mayo Clinic - Rochester
North Carolina
- University North Carolina at Chapel Hill - Chapel Hill
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-08-17 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05654506
The ClinicalTrials.gov registry entry for NCT05654506 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Proliferative Glomerulonephritis With Monoclonal IgG Deposits appearing as the primary indexed condition, and to 1 intervention - of which Daratumumab is the first listed.
NCT05654506 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Minnesota, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05654506 about?
NCT05654506 is a clinical study titled "Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits". The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
What is the current status of trial NCT05654506?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2023-08-17. Estimated completion is 2026-08.
What conditions does trial NCT05654506 study?
This clinical trial studies the following conditions: Proliferative Glomerulonephritis With Monoclonal IgG Deposits.
What interventions are being tested in trial NCT05654506?
The interventions under investigation include: Daratumumab (DRUG).
Who is sponsoring clinical trial NCT05654506?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05654506 being conducted?
This trial has 4 study locations across Florida, Minnesota, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.